Immuno-Oncology Xchange - Boston - 2024

- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
12:20 13:20

Networking Lunch
Clinical Development
- Clinical Development
11:20 12:20

Project Optimus ' The impact on protocol design and requirements

Sponsor-led Roundtable by Catalyst Clinical Research

Meredith Manuel, Executive Director, Consulting - Catalyst Clinical Research
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
17:40 18:40

Evening Drinks Reception
Tumor Microenvironment (TME)
- Tumor Microenvironment (TME)
16:40 17:40

How to overcome suppressive Tumor Microenvironment, Mechanism, Hurdles, and Innovative Therapeutic Modalities.

What are the mechanisms driving suppressive tumor microenvironment? What are the novel therapeutic m ...

Tony Arulanandam, SVP and Head R&D - Cytovia Therapeutics
Translational Research
- Translational Research
16:40 17:40

Using multiplex immunophenotyping to understand anti-tumor immunity

Chris Dupont, Associate Director (Clinical Translational Lead) - Adaptimmune
Immune Biomarkers
- Immune Biomarkers
16:40 17:40

Pharmacodynamic and predictive biomarkers for IO from preclinical to clinical stages

Dan Felitsky, President and CSO - Sfida Ventures
Translational Research
- Translational Research
15:00 15:30

Poster Session: A Direct CAR-Function-Based Library Screening Platform for Developing Fully Human BCMA CAR-T Cell Therapies

Musheng Bao, Head of Biology - Nona Biosciences
Translational Research
- Translational Research
15:00 15:30

Poster Session: Quantification of Single Cell Vector Copy Number in CAR T Cell Products Utilizing a Novel Microfluidic Technology
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
14:25 14:55

1-2-1 Meetings/Networking Break
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
13:55 14:25

1-2-1 Meetings/Networking Break
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
13:20 13:50

Spotlight Presentation: Navigating Precision Oncology Clinical Trials: Paradigm Shifts Critical for Current Trial Needs

Jimmy El Hokayem, Vice President, Program Development and Medical Insights - Biorasi
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
08:00 08:30

Registration
Immune Biomarkers
- Immune Biomarkers
11:20 12:20

Developing autoantibody signatures to predict disease recurrence and immune-related adverse events in patients receiving adjuvant immunotherapy

Scott Paschke, VP of Business Development - CDI Labs
Immune Biomarkers
- Immune Biomarkers
11:20 12:20

Multi-omic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?

Michael F. Goldberg, Director of Immunology - BostonGene
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
11:10 11:20

Morning Refreshments
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
10:40 11:10

1-2-1 Meetings/Networking Break
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
10:10 10:40

1-2-1 Meetings/Networking Break
Tumor Microenvironment (TME)
- Tumor Microenvironment (TME)
09:05 10:05

Learning from patient-derived autoantibodies to understand human tumor biology and identify new targets.
Clinical Development
- Clinical Development
09:05 10:05

Biomarker-driven surrogate endpoints to accelerate clinical development in immuno-oncology

Varsha Sundaresan, Oncology Clinical Biomarker Lead - Takeda
Translational Research
- Translational Research
09:05 10:05

Translational immune modulating strategies to develop effective therapeutics to enhance immune cell engagement and access to tumors

Sadhak Sengupta, Senior Director R&D - IN8bio
Immune Biomarkers
- Immune Biomarkers
09:05 10:05

Identification of specific immune biomarkers in blood for gene-edited cellular therapeutics

Lalit Kumar, Director of Clinical Bioanalytics and Translational Science - Beam Therapeutics
- Clinical Development
- Immune Biomarkers
- Translational Research
- Tumor Microenvironment (TME)
08:30 09:00

Opening Keynote Presentation: Exploring the potential: harnessing ctDNA MRD in immune-oncology treatment for solid tumors

Chun (Michael) Chen, Scientist, Translational Medicine - Burning Rock Dx